Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 11/20 | 0.44 |
| ▸ | NMT2 | O60551 | 10/20 | 0.44 |
| ▸ | TLR2 | O60603 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.41 |
| ▸ | PRKACA | P17612 | 2/20 | 0.41 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.41 |
| ▸ | NPY1R | P25929 | 2/20 | 0.37 |
| ▸ | NPY2R | P49146 | 2/20 | 0.37 |
| ▸ | NPY4R | P50391 | 2/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23436462 | 0.92 | NMT1 (0.46) | NMT1NMT2TLR2ROCK2PRKACA | |
| SCHEMBL20889000 | 0.92 | NMT1 (0.46) | NMT1NMT2TLR2ROCK2PRKACA | |
| SCHEMBL20340684 | 0.89 | FAP (0.37) | NMT1NMT2TLR2NPY1RNPY2R | |
| SCHEMBL17722906 | 0.88 | NMT1 (0.48) | NMT1NMT2TLR2ROCK2PRKACA | |
| SCHEMBL18909077 | 0.86 | NMT1 (0.48) | NMT1NMT2TLR2ROCK2PRKACA | |
| SCHEMBL22668934 | 0.84 | NPY4R (0.38) | NMT1NMT2TLR2NPY1RNPY2R | |
| SCHEMBL21465999 | 0.84 | FAP (0.41) | ROCK2NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL18910973 | 0.84 | NMT1 (0.40) | NMT1NMT2TLR2NPY1RNPY2R | |
| SCHEMBL20340675 | 0.84 | NMT1 (0.43) | NMT1NMT2TLR2NPY1RNPY2R | |
| SCHEMBL21972921 | 0.82 | NMT1 (0.40) | NMT1NMT2TLR2ROCK2PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220396631-A1 | TRISPECIFIC BINDING MOLECULES AGAINST BCMA AND USES THEREOF | NOVARTIS AG (CH) | 2022-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220396631-A1 | TRISPECIFIC BINDING MOLECULES AGAINST BCMA AND USES THEREOF | CD2, CD2BP2, CD22 | NMT1 1317/4885NMT2 1971/4885TLR2 1223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.